The QLDS: a scale for the measurement of quality of life in depression.
about
Adaptation of the QoL-AGHDA scale for adults with growth hormone deficiency in four Slavic languagesTranslation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaireDuloxetine in the treatment of major depressive disorder: an open-label studyDevelopment of the ASQoL: a quality of life instrument specific to ankylosing spondylitisImproved Health-Related Quality of Life and Reduced Productivity Loss After Treatment With Bupropion Sustained Release: A Study in Patients With Major DepressionBiology and therapy of fibromyalgia. New therapies in fibromyalgiaPatients' needs, satisfaction, and health related quality of life: towards a comprehensive modelThe efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trialsUsefulness of EQ-5D in assessing health status in primary care patients with major depressive disorderThe value of the qualitative method for adaptation of a disease-specific quality of life assessment instrument: the case of the Rheumatoid Arthritis Quality of Life Scale (RAQoL) in EstoniaDevelopment and validation of a quality of life questionnaire for patients with colostomy or ileostomy.Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential AnalysisVoice restoration following total laryngectomy by tracheoesophageal prosthesis: effect on patients' quality of life and voice handicap in Jordan.Quality of life--a measure too far?Quality of life and the ICIDH: towards an integrated conceptual model for rehabilitation outcomes research.Comparative efficacy of the Cognitive Behavioral Analysis System of Psychotherapy versus supportive psychotherapy for early onset chronic depression: design and rationale of a multisite randomized controlled trial.Quality of life as patient-reported outcomes: principles of assessment.Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD).Development of the US PSORIQoL: a psoriasis-specific measure of quality of life.Development and preliminary validation of Brace Questionnaire (BrQ): a new instrument for measuring quality of life of brace treated scolioticsDeriving reference values and utilities for the QoL-AGHDA in adult GHDSynchrony of change in depressive symptoms, health status, and quality of life in persons with clinical depressionThe development of patient-reported outcome indices for multiple sclerosis (PRIMUS).Efficacy and safety of the TVT-SECUR® and impact on quality of life in women with stress urinary incontinence: a 2-year follow-up.Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science.Internet-delivered cognitive control training as a preventive intervention for remitted depressed patients: Protocol for a randomized controlled trial.Adaptation of Chinese and English versions of the Psoriatic Arthritis Quality of Life (PsAQoL) scale for use in SingaporeDuloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression.Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacementAdaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-CanadianEfficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentaryDo productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden.Composite scores in comparative effectiveness research: counterbalancing parsimony and dimensionality in patient-reported outcomes.Quality of life in mental disorders: challenges for research and clinical practice.A qualitative study of the impact of Crohn's disease from a patient's perspective.Measuring quality of life in oncology: is it worthwhile? I. Meaning, purposes and controversies.Towards more effective public health programming for injection drug users: development and evaluation of the injection drug user quality of life scale.A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treat
P2860
Q21245610-AB3E0CEA-3D0E-4930-8E2F-822D10718FB2Q21245615-36712B75-F555-44D2-83CE-1914EE4D564FQ24565020-E325A3A8-71FD-48BA-ABFA-7AFE6D982975Q24674389-5DB69D3E-93D1-4F7D-99DD-E7EFDA874378Q24683006-9A3FB1B6-13E6-4176-9C2F-206D3FA8F45BQ24684137-57B59606-38BA-496D-B18E-B79C92A611E3Q24792040-8DB4B015-997D-428A-A518-F52465FA39A2Q24795674-02407D3C-8703-48AF-A07B-48593707E1B0Q24802062-FA82AF70-D0A4-4B14-824F-E058F9DB5B2AQ24803182-B28D8811-D682-4E91-9F9C-DDE9F0F57639Q24812346-8C8F5E64-3662-4025-AD34-10CEECE6C673Q28736049-CFFD5560-FEBB-4F75-BB86-A77471618AC3Q30494877-1D1B34EC-32F7-4592-A8C5-57FFD97A9AD6Q33578048-A385BF46-7052-4DE0-8A0D-12DB83DACAD3Q33634992-D2491888-7620-49C6-B341-053E7DFA0095Q33995208-828571B0-C635-44E3-BA0C-8A16EE47DD64Q34074648-C0AE2D22-6BF0-450F-8749-9BA22CFE6500Q34224524-27A153EA-AA06-449C-A91A-7C6018EEF7DFQ34302550-F99AE8C9-CEC2-472D-8F8F-622F980D8C79Q34424519-947CEB37-9A83-4F05-9A4C-47F422CD9C2CQ34535625-1034A387-5873-4A81-8705-C8B1B91316B6Q34804255-519FBDA8-292E-4174-8949-0AC63DE0DA5BQ34882823-F7EE507C-6085-45EC-B654-35BFE563EB75Q34989085-3BF5398E-A605-497E-A224-3B2120746180Q35019600-8BC22274-D6A0-469A-B539-C25851A32CDCQ35206125-7A197BD5-0295-486C-B1EE-85863A246B57Q35657301-8FBA957D-6523-4550-BA5C-43FDA7685D89Q36166729-CFFB9CAB-6CE5-4202-AAFF-FD415F793B39Q36489025-48DD41C0-59FD-492B-9678-B96D08D0D497Q36898845-210E782F-CFBA-40F5-9828-551EDC659F1CQ37114630-D4A860A7-F074-490B-8FC1-AB20243F2C30Q37449200-0F3F6FC2-7EC0-4792-BEE4-A1A7B4815225Q37872289-E3ACDC84-4299-46E1-BF5F-A1DCF45A0363Q38057110-2F98722E-6082-4A40-AD77-F71294B47B9BQ38256058-D7276297-770F-4D4A-99DF-4775D397A3FDQ39106680-25A793DE-A043-45DF-A44E-A8C650BAA62AQ40080076-24721A17-E077-4F51-A109-8ECECC40E75BQ40927241-6CE7B8F4-3B84-45B6-B34C-5CA4491954DEQ44474511-A3AAF519-1965-474E-99CB-108A2D34B8B2Q44983991-BF3712E4-D62F-467E-9FA4-BA2BF23C52C3
P2860
The QLDS: a scale for the measurement of quality of life in depression.
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The QLDS: a scale for the measurement of quality of life in depression.
@ast
The QLDS: a scale for the measurement of quality of life in depression.
@en
type
label
The QLDS: a scale for the measurement of quality of life in depression.
@ast
The QLDS: a scale for the measurement of quality of life in depression.
@en
prefLabel
The QLDS: a scale for the measurement of quality of life in depression.
@ast
The QLDS: a scale for the measurement of quality of life in depression.
@en
P1433
P1476
The QLDS: a scale for the measurement of quality of life in depression.
@en
P2093
P304
P356
10.1016/0168-8510(92)90004-U
P577
1992-10-01T00:00:00Z